See more : MDxHealth SA (0O8G.L) Income Statement Analysis – Financial Results
Complete financial analysis of Seegene, Inc. (096530.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Seegene, Inc., a leading company in the Medical – Specialties industry within the Healthcare sector.
- HORIZON FIXTURE GROUP CO LTD (6957.TW) Income Statement Analysis – Financial Results
- XPAC Acquisition Corp. (XPAXW) Income Statement Analysis – Financial Results
- Poolia AB (publ) (POOL-B.ST) Income Statement Analysis – Financial Results
- Harish Textile Engineers Limit (HARISH.BO) Income Statement Analysis – Financial Results
- Inhibrx, Inc. Ex-distribution When-Issued (INBXV) Income Statement Analysis – Financial Results
Seegene, Inc. (096530.KQ)
About Seegene, Inc.
Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of six SNPs in factor II, factor V, and MTHFR genes; BRAF mutation characteristic for papillary thyroid carcinoma from samples of thyroid tissue, fine needle aspiration biopsy, H&E slides, and paraffin-embedded tissues; Apolipoprotein E genotypes; and BCR/ABL fusion gene from blood and whole bone marrow. In addition, it offers PCR machines; vial cap management systems; nucleic acid extraction systems; automated liquid handling workstations from nucleic acid extraction to PCR setup; and real-time PCR detection systems. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 367.38B | 853.56B | 1,370.83B | 1,125.22B | 121.95B | 102.26B | 88.92B | 73.69B | 65.14B | 64.41B | 58.99B | 51.71B |
| Cost of Revenue | 187.30B | 387.41B | 312.10B | 282.50B | 50.27B | 41.98B | 33.20B | 27.40B | 24.10B | 17.58B | 15.21B | 16.61B |
| Gross Profit | 180.07B | 466.15B | 1,058.73B | 842.72B | 71.68B | 60.28B | 55.72B | 46.29B | 41.04B | 46.83B | 43.78B | 35.10B |
| Gross Profit Ratio | 49.02% | 54.61% | 77.23% | 74.89% | 58.78% | 58.95% | 62.66% | 62.82% | 63.00% | 72.70% | 74.21% | 67.88% |
| Research & Development | 72.73B | 94.40B | 75.58B | 25.95B | 9.65B | 10.28B | 12.60B | 2.38B | 1.74B | 2.81B | 2.80B | 1.58B |
| General & Administrative | 35.11B | 44.22B | 49.68B | 18.65B | 7.77B | 8.33B | 7.28B | 6.44B | 5.79B | 5.29B | 4.41B | 20.80B |
| Selling & Marketing | 30.37B | 44.56B | 51.37B | 37.62B | 8.90B | 7.75B | 6.84B | 6.10B | 5.10B | 4.44B | 2.21B | 488.99M |
| SG&A | 138.07B | 190.83B | 316.49B | 140.58B | 39.61B | 39.74B | 35.63B | 33.83B | 30.66B | 28.42B | 24.46B | 21.29B |
| Other Expenses | 0.00 | 1.75B | 1.61B | 902.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 210.08B | 285.22B | 392.07B | 166.53B | 49.26B | 50.01B | 48.23B | 36.21B | 32.40B | 35.07B | 31.23B | 24.35B |
| Cost & Expenses | 397.38B | 672.64B | 704.17B | 449.03B | 99.53B | 92.00B | 81.43B | 63.61B | 56.50B | 52.65B | 46.44B | 40.96B |
| Interest Income | 17.50B | 6.75B | 1.29B | 808.45M | 816.38M | 54.75M | 882.50M | 1.05B | 835.63M | 963.90M | 561.05M | 322.21M |
| Interest Expense | 6.22B | 5.45B | 3.77B | 1.40B | 485.64M | 397.77M | 1.64B | 2.17B | 1.62B | 1.75B | 1.34B | 1.38B |
| Depreciation & Amortization | 65.71B | 57.92B | 36.26B | 17.44B | 10.18B | 7.74B | 6.38B | 6.55B | 6.04B | 5.66B | 3.23B | -12.23B |
| EBITDA | 67.28B | 280.08B | 715.12B | 693.63B | 32.60B | 18.01B | 11.00B | 18.61B | 14.67B | 16.78B | 17.32B | 14.20B |
| EBITDA Ratio | 18.31% | 27.98% | 51.28% | 61.64% | 26.73% | 17.61% | 15.60% | 22.58% | 22.53% | 26.05% | 29.36% | -3.47% |
| Operating Income | -30.01B | 180.93B | 666.66B | 676.19B | 22.42B | 10.27B | 7.49B | 10.08B | 8.64B | 11.12B | 14.09B | 12.23B |
| Operating Income Ratio | -8.17% | 21.20% | 48.63% | 60.09% | 18.39% | 10.04% | 8.42% | 13.68% | 13.26% | 17.26% | 23.88% | 23.64% |
| Total Other Income/Expenses | 28.60B | 6.22B | -13.24B | -7.05B | -4.98B | -6.97B | -4.58B | -670.45M | 280.32M | -321.55M | -2.10B | -1.80B |
| Income Before Tax | -1.41B | 216.71B | 675.09B | 654.33B | 27.06B | 10.67B | 2.98B | 9.87B | 8.83B | 10.80B | 11.99B | 10.43B |
| Income Before Tax Ratio | -0.38% | 25.39% | 49.25% | 58.15% | 22.19% | 10.43% | 3.35% | 13.39% | 13.56% | 16.76% | 20.32% | 20.17% |
| Income Tax Expense | -2.15B | 43.13B | 151.60B | 165.99B | 994.75M | 586.72M | -765.67M | 2.25B | 2.14B | 1.65B | 2.42B | 1.33B |
| Net Income | 669.01M | 182.14B | 536.56B | 502.28B | 26.67B | 10.10B | 3.19B | 7.12B | 6.77B | 9.14B | 9.57B | 9.10B |
| Net Income Ratio | 0.18% | 21.34% | 39.14% | 44.64% | 21.87% | 9.87% | 3.58% | 9.67% | 10.40% | 14.19% | 16.23% | 17.60% |
| EPS | 14.19 | 3.59K | 10.36K | 9.66K | 513.08 | 194.26 | 61.16 | 136.48 | 131.96 | 182.00 | 195.00 | 233.00 |
| EPS Diluted | 14.19 | 3.59K | 10.36K | 9.66K | 513.08 | 194.26 | 61.16 | 136.48 | 131.96 | 182.00 | 195.00 | 233.00 |
| Weighted Avg Shares Out | 47.15M | 50.79M | 51.80M | 51.98M | 51.98M | 51.98M | 52.11M | 52.19M | 51.33M | 50.23M | 49.09M | 39.07M |
| Weighted Avg Shares Out (Dil) | 47.15M | 50.79M | 51.80M | 51.98M | 51.98M | 51.98M | 52.11M | 52.19M | 51.33M | 50.23M | 49.09M | 39.07M |
Source: https://incomestatements.info
Category: Stock Reports